Futura Medical Regulatory News (FUM)

Application for Block Listing

26 November 2018

Futura Medical plc (AIM: FUM) (the "Company"), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, today announces that an application has been made to the London Stock Exchange to extend its block listings of securities by a total of 1,765,000 ordinary shares of 0.2 pence each (the "New Ordinary Shares") which may arise pursuant to the exercise of options under the Company's EMI Share Option Scheme and its Unapproved Share Incentive Scheme.

It is expected that admission of the New Ordinary Shares will become effective on or around 30 November 2018 ("Admission"). Following Admission, the Company will notify its Schedule Six (block listing interim review) update for the period from 31 May 2018 to 30 November 2018.

Any New Ordinary Shares issued will be credited as fully paid and will rank pari passu in all respects with the existing Ordinary Shares of the Company.

For further information please contact:

Futura Medical plc

James Barder, Chief Executive

Angela Hildreth, Finance Director and COO

Email: Investor.relations@futuramedical.com

Tel: +44 (0) 1483 685 670

Nominated Adviser and Broker:

N+1 Singer

Aubrey Powell/ Ben Farrow (Corporate Finance)

Tom Salvesen/ Mia Gardner (Corporate Broking)

Tel: +44 (0) 20 7496 3000

For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Hollie Vile/ Ellie Blackwell

Email: futuramedical@optimumcomms.com

Tel: +44 (0) 203 950 9144

Notes to editors

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com